National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
Topics
- (-) Behavioral Health (12)
- Children/Adolescents (1)
- Comparative Effectiveness (7)
- Depression (3)
- Elderly (1)
- (-) Evidence-Based Practice (12)
- Guidelines (1)
- Hospitalization (2)
- Human Immunodeficiency Virus (HIV) (1)
- Inpatient Care (2)
- Maternal Care (1)
- Medicaid (1)
- (-) Medication (12)
- Neurological Disorders (2)
- Obesity (2)
- Opioids (1)
- Outcomes (5)
- Patient-Centered Outcomes Research (5)
- Patient Safety (1)
- Practice Patterns (1)
- Pregnancy (2)
- Prevention (2)
- Substance Abuse (1)
- Tobacco Use (1)
- Treatments (2)
- U.S. Preventive Services Task Force (USPSTF) (1)
- Women (2)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 12 of 12 Research Studies DisplayedKorthuis PT, Cook RR, Lum PJ
HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.
Opioid Use Disorder (OUD) treatment medications can improve outcomes for human immunodeficiency virus (HIV) and also reduce opioid use. The purpose of the study was to determine if outpatient naltrexone treatment could also reduce opioid use and improve outcomes for HIV. The researchers reported that enrollment was stopped early because of slower than expected recruitment, resulting in 114 final participants with untreated OUD and HIV, with 62% positive for fentanyl, 60% positive for cocaine, and 47% positive for other opioids at the baseline. The intervention compared treatment as usual (TAU) of methadone or buprenorphine with extended-release naltrexone (XR-NTX) on group differences in viral suppression at 24 weeks and past 30-day use of opioids at 24 weeks. The study reported that at 24 weeks the outcome of viral suppression was similar for TAU and XR-NTX, and that fewer XR-NTX participants initiated medication than TAU participants. The outcome of previous 30-day use of opioids was similar for TAU as compared to XR-NTX. Of those participants who did initiate medication, those administered XR-NTX experienced less days of opioid use when compared with TAU in the prior 30 days. The researchers reported that the study evidence was not conclusive but did support that XR-NTX is not inferior to TAU for HIV viral suppression, and that study participants who started XR-NTX used less opioids at 24 weeks than participants who were administered TAU.
AHRQ-funded; HS026370.
Citation: Korthuis PT, Cook RR, Lum PJ .
HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.
Addiction 2022 Jul;117(7):1961-71. doi: 10.1111/add.15836..
Keywords: Human Immunodeficiency Virus (HIV), Opioids, Substance Abuse, Behavioral Health, Medication, Treatments, Patient-Centered Outcomes Research, Outcomes, Evidence-Based Practice
Penfold RB, Thompson EE, Hilt RJ
Development of a symptom-focused model to guide the prescribing of antipsychotics in children and adolescents: results of the first phase of the Safer Use of Antipsychotics in Youth (SUAY) Clinical Trial.
The purpose of this study was to develop a new approach to prescribing guidelines as part of a pragmatic trial, Safer Use of Antipsychotics in Youth (SUAY; ClinicalTrials.gov Identifier: NCT03448575), which supports prescribers in delivering high-quality mental health care to youths. Prescribing guidelines are often ignored because they do not incorporate the real-world availability of first-line psychosocial treatments, comorbid conditions, and clinical complexity. The investigators indicated that their approach addressed some of these concerns.
AHRQ-funded; HS026001; HS023258.
Citation: Penfold RB, Thompson EE, Hilt RJ .
Development of a symptom-focused model to guide the prescribing of antipsychotics in children and adolescents: results of the first phase of the Safer Use of Antipsychotics in Youth (SUAY) Clinical Trial.
J Am Acad Child Adolesc Psychiatry 2022 Jan;61(1):93-102. doi: 10.1016/j.jaac.2021.04.010..
Keywords: Children/Adolescents, Medication, Behavioral Health, Patient Safety, Guidelines, Evidence-Based Practice
Viswanathan M, Cook Middleton J, Stuebe AM
Maternal, fetal, and child outcomes of mental health treatments in women: a meta‐analysis of pharmacotherapy
The authors systematically reviewed evidence on pharmacotherapy for perinatal mental health disorders. The investigators concluded that evidence from few studies supported the use of pharmacotherapy for perinatal mental health disorders. Although many studies reported on adverse events, they could not rule out underlying disease severity as the cause of the association between exposures and adverse events.
AHRQ-funded; 290201500011I.
Citation: Viswanathan M, Cook Middleton J, Stuebe AM .
Maternal, fetal, and child outcomes of mental health treatments in women: a meta‐analysis of pharmacotherapy
Psych Res Clin Pract 2021 Sep;3(3):123-40. doi: 10.1176/appi.prcp.20210001..
Keywords: Behavioral Health, Women, Maternal Care, Pregnancy, Medication, Evidence-Based Practice
Kohler-Forsberg O, Sylvia LG, Fung V
Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: findings from the Bipolar CHOICE and LiTMUS trials.
The purpose of this study was to examine the clinical efficacy of adjunctive antidepressants. In this large cohort of outpatients with bipolar disorder, findings showed that clinically indicated and guideline-based adjunctive antidepressant treatment was not associated with lower depressive symptoms or higher mania symptoms.
AHRQ-funded; HS019371.
Citation: Kohler-Forsberg O, Sylvia LG, Fung V .
Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: findings from the Bipolar CHOICE and LiTMUS trials.
Depress Anxiety 2021 Feb;38(2):114-23. doi: 10.1002/da.23069..
Keywords: Depression, Behavioral Health, Medication, Comparative Effectiveness, Evidence-Based Practice, Outcomes
Yaramala SR, McElroy SL, Geske J
The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study.
Lithium and quetiapine can cause weight gain, but their comparative longer term anthropometric effects are unknown, as are the potential moderating effects of baseline binge-eating (BE) behavior. In this research, the investigators assessed 6 month changes in body weight, body mass index (BMI) and waist circumference in 482 adults with DSM-IV bipolar disorders who participated in a comparative effectiveness study of lithium and quetiapine with evidence-based adjunctive treatment (Bipolar CHOICE).
AHRQ-funded; HS019371.
Citation: Yaramala SR, McElroy SL, Geske J .
The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study.
months of treatment: Findings from the bipolar CHOICE study.
J Affect Disord 2020 Apr 1;266:772-81. doi: 10.1016/j.jad.2018.09.025.
.
J Affect Disord 2020 Apr 1;266:772-81. doi: 10.1016/j.jad.2018.09.025.
.
Keywords: Behavioral Health, Medication, Obesity, Comparative Effectiveness, Patient-Centered Outcomes Research, Evidence-Based Practice, Outcomes
Ochs-Ross R, Daly EJ, Zhang Y
Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3.
This phase 3 double-blind study randomized patients with treatment-resistant depression age 65 or older to flexibly-dosed esketamine nasal spray and new oral antidepressant (esketamine/antidepressant) or new oral antidepressant and placebo nasal spray (antidepressant/placebo). The primary endpoint was change in the Montgomery-Asberg Depression Rating Scale (MADRS) over 28 days from baseline. Results showed that esketamine/antidepressant did not achieve statistical significance for patients ages 75 and older; however, greater differences were seen for patients ages 65-74 and patients with earlier onset of depression younger than age 55.
AHRQ-funded; HS023000.
Citation: Ochs-Ross R, Daly EJ, Zhang Y .
Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3.
Am J Geriatr Psychiatry 2020 Feb;28(2):121-41. doi: 10.1016/j.jagp.2019.10.008..
Keywords: Medication, Depression, Behavioral Health, Elderly, Comparative Effectiveness, Treatments, Evidence-Based Practice
Oh ES, Needham DM, Nikooie R
Antipsychotics for preventing delirium in hospitalized adults: a systematic review.
The purpose of this study was to conduct a systematic review evaluating the benefits and harms of antipsychotics to treat delirium in adults. Results showed that there was little evidence demonstrating neurologic harms associated with short-term use of antipsychotics for treating delirium in adult inpatients, but potentially harmful cardiac effects tended to occur more frequently. Current evidence does not support routine use of haloperidol or second-generation antipsychotics to treat delirium in adult inpatients.
AHRQ-funded; 290201500006I.
Citation: Oh ES, Needham DM, Nikooie R .
Antipsychotics for preventing delirium in hospitalized adults: a systematic review.
Ann Intern Med 2019 Oct 1;171(7):474-84. doi: 10.7326/m19-1859..
Keywords: Neurological Disorders, Medication, Hospitalization, Inpatient Care, Patient-Centered Outcomes Research, Outcomes, Evidence-Based Practice, Comparative Effectiveness, Behavioral Health, Prevention
Nikooie R, Neufeld KJ, Oh ES
Antipsychotics for treating delirium in hospitalized adults: a systematic review.
The purpose of this study was to conduct a systematic review evaluating the benefits and harms of antipsychotics to treat delirium in adults. Results showed that there was little evidence demonstrating neurologic harms associated with short-term use of antipsychotics for treating delirium in adult inpatients, but potentially harmful cardiac effects tended to occur more frequently. Current evidence does not support routine use of haloperidol or second-generation antipsychotics to treat delirium in adult inpatients.
AHRQ-funded; 290201500006I.
Citation: Nikooie R, Neufeld KJ, Oh ES .
Antipsychotics for treating delirium in hospitalized adults: a systematic review.
Ann Intern Med 2019 Oct 1;171(7):485-95. doi: 10.7326/m19-1860.
.
.
Keywords: Neurological Disorders, Medication, Hospitalization, Inpatient Care, Patient-Centered Outcomes Research, Outcomes, Evidence-Based Practice, Comparative Effectiveness, Behavioral Health
Mathew SJ, Wilkinson ST, Altinay M
ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with treatment-resistant depression: The ELEKT-D study protocol.
This article discusses the protocol that will be used for an ongoing study to compare electroconvulsive therapy (ECT) vs. ketamine for patients with treatment-resistant major depressive disorder (MDD). The study is being called ELEKT-D. Patients will be randomized between thrice-weekly ECT treatments or intravenous ketamine given twice weekly for 3-5 weeks. The objective of the study is to determine if ketamine will retain 90% of the ECT treatment effect. Additional outcomes to be measured include remission rates, depression severity, cognitive functioning, quality of live, adverse events, and tolerability.
AHRQ-funded; HS023000.
Citation: Mathew SJ, Wilkinson ST, Altinay M .
ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with treatment-resistant depression: The ELEKT-D study protocol.
Contemp Clin Trials 2019 Feb;77:19-26. doi: 10.1016/j.cct.2018.12.009..
Keywords: Depression, Behavioral Health, Medication, Comparative Effectiveness, Patient-Centered Outcomes Research, Evidence-Based Practice
Brownley KA, Berkman ND, Peat CM
Binge-eating disorder in adults: a systematic review and meta-analysis.
This review summarized evidence about the benefits and harms of psychological and pharmacologic therapies for adults with binge-eating disorder. It concluded that cognitive behavioral therapy, lisdexamfetamine, SGAs, and topiramate reduced binge eating and related psychopathology, and lisdexamfetamine and topiramate reduced weight in adults with binge-eating disorder.
AHRQ-funded; 290201200008U.
Citation: Brownley KA, Berkman ND, Peat CM .
Binge-eating disorder in adults: a systematic review and meta-analysis.
Ann Intern Med 2016 Sep 20;165(6):409-20. doi: 10.7326/m15-2455.
.
.
Keywords: Obesity, Medication, Evidence-Based Practice, Behavioral Health, Comparative Effectiveness
Patnode CD, Henderson JT, Thompson JH
Behavioral counseling and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women: a review of reviews for the U.S. Preventive Services Task Force.
The researchers reviewed the effectiveness and safety of pharmacotherapy and behavioral interventions for tobacco cessation. They concluded that behavioral and pharmacotherapy interventions improve rates of smoking cessation among the general adult population, alone or in combination. Data on the effectiveness and safety of electronic nicotine delivery systems are limited.
AHRQ-funded; 290201200015I.
Citation: Patnode CD, Henderson JT, Thompson JH .
Behavioral counseling and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women: a review of reviews for the U.S. Preventive Services Task Force.
Ann Intern Med 2015 Oct 20;163(8):608-21. doi: 10.7326/m15-0171..
Keywords: Behavioral Health, Evidence-Based Practice, Medication, Pregnancy, Prevention, Tobacco Use, U.S. Preventive Services Task Force (USPSTF), Women
Finnerty M, Neese-Todd S, Bilder S
Best practices: MEDNET: a multistate policy maker-researcher collaboration to improve prescribing practices.
The authors describe the Medicaid/ Mental Health Network for Evidence-Based Treatment (MEDNET), the first multistate Medicaid QI collaborative to focus on improving psychotropic prescribing. In particular, this article includes the development, infrastructure challenges, and early evidence of success of this public-academic partnership.
AHRQ-funded; HSO19937; HS021112.
Citation: Finnerty M, Neese-Todd S, Bilder S .
Best practices: MEDNET: a multistate policy maker-researcher collaboration to improve prescribing practices.
Psychiatr Serv 2014 Nov 1;65(11):1297-9. doi: 10.1176/appi.ps.201400343..
Keywords: Behavioral Health, Evidence-Based Practice, Medication, Medicaid, Practice Patterns